EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

This example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2. The study is designed as a biomarker-enriched, open-label, non-randomized trial with a dose-escalation safety lead-in followed by an expansion cohort at the recommended Phase 2 dose (RP2D).

NCT Number	NCT07617805
Lead Sponsor	Beijing Biotech
Conditions	Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
Enrollment	42 participants
Start Date	2026-03-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-05-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-01